Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phase I trial of a humanized, Fc receptor nonbinding anti-CD3 antibody, hu12F6mu in patients receiving renal allografts.

mAbs - 1 Jan 2000

Li Jing, Zhou Bo, Shentu Jianzhong, Du Li, Tan Min, Hou Sheng, Qian Weizhu, Li Bohua, Zhang Dapeng, Dai Jianxin, Wang Hao, Zhang Xu, Chen Jianghua, Guo Yajun

Abstract excerpt

Hu12F6mu is an Fc-mutated, humanized anti-CD3 antibody developed in our lab. The aim of this study was to assess single dose escalation pharmacokinetics (PK) and safety profile of hu12F6mu and to measure the effects of the antibody on levels of circulating T cells over time. Twenty-seven patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Intravenous
Share to CD3 Complex
Share to Graft Rejection

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunoglobulin Fc Fragments

Share to Lymphocyte Count

Share to Postoperative Complications

Share to Receptors, Fc

Share to Transplantation, Homologous

Source

Open in PubMed Open full text

Identifiers

PMID: 20519962
DOI: 10.4161/mabs.12305
PMCID: PMC3180091

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20519962-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase I trial of a humanized, Fc receptor nonbinding anti-CD3 antibody, hu12F6mu in patients receiving renal allografts.PMID 20519962Read ↗

CD38 monoclonal antibody felzartamab for late antibody-mediated rejection: a phase II drug evaluationSemantic proximity Read ↗

Gene expression profile of human T cells following a single stimulation of peripheral blood mononuclear cells with anti-CD3 antibodiesSemantic proximity Read ↗

A humanized anti-CD3 antibody, HuM291, with low mitogenic activity, mediates complete and reversible T-cell depletion in chimpanzees.Semantic proximity Read ↗

In vitro characterization of five humanized OKT3 effector function variant antibodies.Semantic proximity Read ↗

Inverse Association Between the Quantity of Human Peripheral Blood CXCR5+IFN-γ+CD8+ T Cells With De Novo DSA Production in the First Year After Kidney Transplant.Semantic proximity Read ↗

Alefacept promotes immunosuppression-free renal allograft survival in nonhuman primates via depletion of recipient memory T cells.Semantic proximity Read ↗

Quantitative Prediction of Human Pharmacokinetics for Fc-Engineered Therapeutic Monoclonal Antibodies With Increased FcRn Binding Mutations After Subcutaneous Injection.Semantic proximity Read ↗

A humanized CD3ε-knock-in mouse model for pre-clinical testing of anti-human CD3 therapy.Semantic proximity Read ↗

[The mutation of anti-CD3 antibody (HIT3a) gene and its expression].Semantic proximity Read ↗

Ex vivo expanded natural regulatory T cells from patients with end-stage renal disease or kidney transplantation are useful for autologous cell therapy.Semantic proximity Read ↗

Ea<sub>3</sub>Mab-20: A Specific Anti-Human EphA3 Monoclonal Antibody for Flow CytometrySemantic proximity Read ↗

Effect of a single amino acid mutation on the activating and immunosuppressive properties of a "humanized" OKT3 monoclonal antibodySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.